

6 manifestaciones en APs

Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study

Maria Antonietta D'Agostino, Georg Schett, Corine Gaillez, Carlos Guerrero, PETRA HANOVA, Tomas Cazeneuve, Maria S. Stoncuix, Marina Backhaus, Gael Mouterde, Maarten Boers, Anne-Marie Duggan, Punit Goyanka and Philip Conaghan. Rheumatology, Fondazione Policlinico Universitario "Gemelli", IRCCS, Rome, Italy, Universitätsklinikum Erlangen, Department of Internal Medicine - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, Novartis Pharma AG, Basel, Switzerland, Dermatológico Country, Jalisco, Mexico, Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee, Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, Rheumatology department, CHU Montpellier, Montpellier, France, Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.

[Acceder](#)

Secukinumab demonstrates superiority over narrow- band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Kulli Kingo, Raquel River Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh, Piotr Jagiello.

[Acceder](#)

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study

Philip J. Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Juergen Rech, Stephen

Hall, Piet Geusens, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, Shephard Mpofu, and on behalf of the FUTURE 1 study group.

[Acceder](#)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C Coates.

[Acceder](#)

Image



Solicitud de información médica

¿Tienes una pregunta específica sobre alguno de nuestros productos o patologías?

[Contacta con nuestro equipo de Información Médica](#)

Source URL:

<https://www.pro.novartis.com/es-es/evidencia-de-secukinumab/6-manifestaciones-en-aps>